$0.25
0.00%
Nasdaq, Mon, Nov 25 2024
ISIN
IL0011327454
Symbol
VBLT
Sector
Industry

Vascular Biogenics Ltd. Stock price

$0.25
+0.00 0.00% 1M
-0.55 69.01% 6M
-1.64 86.88% YTD
-3.74 93.79% 1Y
-76.75 99.68% 3Y
-42.45 99.42% 5Y
-219.55 99.89% 10Y
Nasdaq, Closing price Mon, Nov 25 2024
+0.00 0.00%
ISIN
IL0011327454
Symbol
VBLT
Sector
Industry

Key metrics

Market capitalization $2.39m
Enterprise Value $100.00k
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 0.21
P/S ratio (TTM) P/S ratio 4.98
P/B ratio (TTM) P/B ratio 0.33
Revenue growth (TTM) Revenue growth -15.91%
Revenue (TTM) Revenue $480.00k
EBIT (operating result TTM) EBIT $-16.35m
Free Cash Flow (TTM) Free Cash Flow $-16.72m
Cash position $4.09m
EPS (TTM) EPS $-7.35
P/E forward negative
Short interest 0.33%
Show more

Is Vascular Biogenics Ltd. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.

Vascular Biogenics Ltd. Stock Analysis

Unlock Scores for Free

Analyst Opinions

1 Analyst has issued a forecast Vascular Biogenics Ltd.:

1x Buy
100%

Analyst Opinions

1 Analyst has issued a forecast Vascular Biogenics Ltd.:

Buy
100%

Financial data from Vascular Biogenics Ltd.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '24
+/-
%
0.48 0.48
0% 0%
100%
- Direct Costs 0.43 0.43
0% 0%
90%
0.42 0.42
0% 0%
88%
- Selling and Administrative Expenses - -
- Research and Development Expense 5.62 5.62
0% 0%
1,171%
-16 -16
0% 0%
-3,335%
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -16 -16
0% 0%
-3,406%
Net Profit -16 -16
0% 0%
-3,325%

In millions USD.

Don't miss a Thing! We will send you all news about Vascular Biogenics Ltd. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

Vascular Biogenics Ltd. is in the clinical-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of first-in-class treatments for cancer. Its programs include cancer, inflammation, and VB-600 which are focused on treating tumors, ovarian cancer, and chronic immune-related indications. The company was founded by Dror Harats and Jacob George on January 27, 2000 and is headquartered in Modi'in, Israel.

Head office Israel
CEO Kaile Zagger
Founded 2014
Website www.notablelabs.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today